Bexobrutideg (NX-5948)

About Nurix Therapeutics

Nurix Therapeutics is a leader in the targeted protein degradation (TPD) space, with a mission to develop breakthrough therapies for cancer and autoimmune diseases by harnessing the body's natural protein disposal systems. The company's core achievement is the development of its integrated DELigase™ discovery platform, which combines DNA-encoded libraries (DEL), artificial intelligence (AI), and deep E3 ligase expertise to rapidly generate novel degrader candidates. Its strategy involves advancing a multi-modal pipeline of oral degraders and antibody-conjugated degraders (DACs), with its lead asset, bexobrutideg (NX-5948), in Phase 2 trials for hematologic cancers. Nurix aims to establish degrader-based medicines as a cornerstone of future patient care through both internal development and strategic partnerships.

About Nurix Therapeutics

Nurix Therapeutics is a leader in the targeted protein degradation (TPD) space, with a mission to develop breakthrough therapies for cancer and autoimmune diseases by harnessing the body's natural protein disposal systems. The company's core achievement is the development of its integrated DELigase™ discovery platform, which combines DNA-encoded libraries (DEL), artificial intelligence (AI), and deep E3 ligase expertise to rapidly generate novel degrader candidates. Its strategy involves advancing a multi-modal pipeline of oral degraders and antibody-conjugated degraders (DACs), with its lead asset, bexobrutideg (NX-5948), in Phase 2 trials for hematologic cancers. Nurix aims to establish degrader-based medicines as a cornerstone of future patient care through both internal development and strategic partnerships.

Therapeutic Areas

Other Relapsed/Refractory B-cell Malignancies Drugs